142 related articles for article (PubMed ID: 37080716)
21. Impact of Anti-tumour Necrosis Factor Agents on the Risk of Colorectal Cancer in Patients with Ulcerative Colitis: Nationwide French Cohort Study.
Charkaoui M; Hajage D; Tubach F; Beaugerie L; Kirchgesner J
J Crohns Colitis; 2022 Jul; 16(6):893-899. PubMed ID: 34657962
[TBL] [Abstract][Full Text] [Related]
22. Interleukin 1β Blockade Reduces Intestinal Inflammation in a Murine Model of Tumor Necrosis Factor-Independent Ulcerative Colitis.
Liso M; Verna G; Cavalcanti E; De Santis S; Armentano R; Tafaro A; Lippolis A; Campiglia P; Gasbarrini A; Mastronardi M; Pizarro TT; Cominelli F; Lopetuso LR; Chieppa M
Cell Mol Gastroenterol Hepatol; 2022; 14(1):151-171. PubMed ID: 35314399
[TBL] [Abstract][Full Text] [Related]
23. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
Olsen T; Goll R; Cui G; Christiansen I; Florholmen J
Cytokine; 2009 May; 46(2):222-7. PubMed ID: 19286392
[TBL] [Abstract][Full Text] [Related]
24. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis.
Olsen T; Goll R; Cui G; Husebekk A; Vonen B; Birketvedt GS; Florholmen J
Scand J Gastroenterol; 2007 Nov; 42(11):1312-20. PubMed ID: 17852866
[TBL] [Abstract][Full Text] [Related]
25. Investigation on the Inhibitory Effect of Wnt-5a on Colonic Mucosal Inflammation in Patients with Ulcerative Colitis.
Uchiyama K; Takagi T; Mizushima K; Asaeda K; Kajiwara M; Kashiwagi S; Minagawa Y; Hotta Y; Tanaka M; Inoue K; Dohi O; Okayama T; Yoshida N; Katada K; Kamada K; Ishikawa T; Yasuda H; Konishi H; Kishimoto M; Naito Y; Itoh Y
Dig Dis Sci; 2022 Oct; 67(10):4760-4769. PubMed ID: 35590045
[TBL] [Abstract][Full Text] [Related]
26. Neutrophil Extracellular Traps Sustain Inflammatory Signals in Ulcerative Colitis.
Dinallo V; Marafini I; Di Fusco D; Laudisi F; Franzè E; Di Grazia A; Figliuzzi MM; Caprioli F; Stolfi C; Monteleone I; Monteleone G
J Crohns Colitis; 2019 May; 13(6):772-784. PubMed ID: 30715224
[TBL] [Abstract][Full Text] [Related]
27. TNF-α-induced down-regulation of CDX2 suppresses MEP1A expression in colitis.
Coskun M; Olsen AK; Holm TL; Kvist PH; Nielsen OH; Riis LB; Olsen J; Troelsen JT
Biochim Biophys Acta; 2012 Jun; 1822(6):843-51. PubMed ID: 22326557
[TBL] [Abstract][Full Text] [Related]
28. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis.
Melgar S; Yeung MM; Bas A; Forsberg G; Suhr O; Oberg A; Hammarstrom S; Danielsson A; Hammarstrom ML
Clin Exp Immunol; 2003 Oct; 134(1):127-37. PubMed ID: 12974765
[TBL] [Abstract][Full Text] [Related]
29. PTK2B regulates immune responses of neutrophils and protects mucosal inflammation in ulcerative colitis.
Zhou G; Zhu F; Zhang H; Wang Y; Yang Y; Jin G; Wang Y; Dong G; Xiong H
FASEB J; 2023 Jul; 37(7):e22967. PubMed ID: 37269155
[TBL] [Abstract][Full Text] [Related]
30. Expression of matrix metalloproteinase-1 and tumor necrosis factor-alpha in ulcerative colitis.
Wang YD; Mao JW
World J Gastroenterol; 2007 Nov; 13(44):5926-32. PubMed ID: 17990358
[TBL] [Abstract][Full Text] [Related]
31. The in vitro and in vivo anti-inflammatory effect of osthole, the major natural coumarin from Cnidium monnieri (L.) Cuss, via the blocking of the activation of the NF-κB and MAPK/p38 pathways.
Fan H; Gao Z; Ji K; Li X; Wu J; Liu Y; Wang X; Liang H; Liu Y; Li X; Liu P; Chen D; Zhao F
Phytomedicine; 2019 May; 58():152864. PubMed ID: 30878874
[TBL] [Abstract][Full Text] [Related]
32. Moxibustion inhibits interleukin-12 and tumor necrosis factor alpha and modulates intestinal flora in rat with ulcerative colitis.
Wang XM; Lu Y; Wu LY; Yu SG; Zhao BX; Hu HY; Wu HG; Bao CH; Liu HR; Wang JH; Yao Y; Hua XG; Guo HY; Shen LR
World J Gastroenterol; 2012 Dec; 18(46):6819-28. PubMed ID: 23239920
[TBL] [Abstract][Full Text] [Related]
33. Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio.
Bertani L; Rossari F; Barberio B; Demarzo MG; Tapete G; Albano E; Baiano Svizzero G; Ceccarelli L; Mumolo MG; Brombin C; de Bortoli N; Bellini M; Marchi S; Bodini G; Savarino E; Costa F
Inflamm Bowel Dis; 2020 Sep; 26(10):1579-1587. PubMed ID: 32232392
[TBL] [Abstract][Full Text] [Related]
34. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
[TBL] [Abstract][Full Text] [Related]
35. Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients.
Obraztsov IV; Shirokikh KE; Obraztsova OI; Shapina MV; Wang MH; Khalif IL
Inflamm Bowel Dis; 2019 Feb; 25(3):524-531. PubMed ID: 30544140
[TBL] [Abstract][Full Text] [Related]
36. Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis.
Zhang J; Wu X; Wei S; Liu C; Wang X; Dong W
Autoimmunity; 2022 Dec; 55(8):538-548. PubMed ID: 35876170
[TBL] [Abstract][Full Text] [Related]
37. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response.
Haberman Y; Karns R; Dexheimer PJ; Schirmer M; Somekh J; Jurickova I; Braun T; Novak E; Bauman L; Collins MH; Mo A; Rosen MJ; Bonkowski E; Gotman N; Marquis A; Nistel M; Rufo PA; Baker SS; Sauer CG; Markowitz J; Pfefferkorn MD; Rosh JR; Boyle BM; Mack DR; Baldassano RN; Shah S; Leleiko NS; Heyman MB; Grifiths AM; Patel AS; Noe JD; Aronow BJ; Kugathasan S; Walters TD; Gibson G; Thomas SD; Mollen K; Shen-Orr S; Huttenhower C; Xavier RJ; Hyams JS; Denson LA
Nat Commun; 2019 Jan; 10(1):38. PubMed ID: 30604764
[TBL] [Abstract][Full Text] [Related]
38. Curative effects of crocin in ulcerative colitis via modulating apoptosis and inflammation.
Albalawi GA; Albalawi MZ; Alsubaie KT; Albalawi AZ; Elewa MAF; Hashem KS; Al-Gayyar MMH
Int Immunopharmacol; 2023 May; 118():110138. PubMed ID: 37030122
[TBL] [Abstract][Full Text] [Related]
39. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
[TBL] [Abstract][Full Text] [Related]
40. A molecular subtyping associated with the cGAS-STING pathway provides novel perspectives on the treatment of ulcerative colitis.
Wang C; Gao X; Li Y; Li C; Ma Z; Sun D; Liang X; Zhang X
Sci Rep; 2024 Jun; 14(1):12683. PubMed ID: 38831059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
